- Home
- Products
FARYDAK (Panobinostat)
FARYDAK (Panobinostat)
- Medicine Name: Farydak
- Generic Name: Panobinostat
- Dosage Form & Strength: Capsules – 10 mg, 15 mg, 20 mg
- Manufactured By: Novartis Pharmaceuticals Corporation
Farydak (panobinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of multiple myeloma in patients who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory agent (such as lenalidomide or thalidomide).
It is used in combination with bortezomib and dexamethasone and has been shown to extend progression-free survival in relapsed/refractory multiple myeloma patients.
Recommended Dosage:
- Starting dose: 20 mg orally, once every other day (Days 1, 3, 5, 8, 10, 12) of a 21-day cycle, for up to 8 cycles
- May be continued for an additional 8 cycles if well tolerated and clinically beneficial
- Total duration: up to 16 cycles (48 weeks)
- Administered with bortezomib (1.3 mg/m² IV) and dexamethasone (20 mg orally)
Missed doses may be taken within 12 hours; do not repeat doses after vomiting.
- Severe Diarrhea: Monitor hydration and electrolytes (potassium, magnesium, phosphate). Begin anti-diarrheal agents at first sign.
- Cardiac Risks: Monitor ECG periodically due to risk of ischemic events and arrhythmias. Correct electrolyte imbalances.
- Bone Marrow Suppression: Includes thrombocytopenia, neutropenia, and anemia. Perform CBC weekly and monitor closely in elderly patients.
- Infection Risk: May increase risk of bacterial, viral, and fungal infections. Monitor patients and initiate prompt anti-infective treatment when needed.
- Liver Dysfunction: Regularly monitor liver enzymes and bilirubin during therapy.
- Pregnancy Warning: Can cause fetal harm. Contraindicated in pregnant women. Women of reproductive potential should use effective contraception.
To Import Farydak into India, the following documents are required:
- Valid prescription from a licensed oncologist
- Relevant diagnostic test reports
- Government-issued patient ID
Order Confirmation:
Orders are processed only after submission of valid prescription and import permit (if required by Indian authorities).
Availability in India:
Farydak is not typically stocked in Indian retail pharmacies. GlobalRareMeds can help legally import it via the Named Patient Import Program, ensuring regulatory compliance.
GlobalRareMeds sources Farydak (Panobinostat) from certified global suppliers across the USA, Canada, Europe, and Australia.
All shipments are processed through our Ambernath, Thane District fulfillment center. Delivery is available to all major Indian cities including Mumbai, Delhi, Chennai, Hyderabad, Kolkata, Bengaluru, Ahmedabad, and Pune.
For assistance or to place an order, contact:
📧 info@globalraremeds.com
📞 +91-99675 15602
📱 WhatsApp: +91-99675 15602
What is the generic name for Farydak?
Panobinostat.
Is Farydak FDA approved?
Yes, Farydak was approved by the U.S. FDA on February 23, 2015.
What foods should I avoid while taking Farydak?
Avoid star fruit, grapefruit (and juice), and pomegranate (and juice), as they can alter drug metabolism.
What forms and strengths is Farydak available in?
Farydak is available as 10 mg, 15 mg, and 20 mg oral capsules.
What are the most common side effects?
Nausea, diarrhea, fatigue, decreased appetite, peripheral edema, vomiting, and fever (pyrexia).
How should Farydak be stored?
Store at 20°C to 25°C (68°F to 77°F). Keep capsules in the original blister pack to protect from light.
Is Farydak available in India?
Farydak can be imported into India through GlobalRareMeds with proper documentation under the Named Patient Program.
How much does Farydak cost in India?
Prices may vary. Contact GlobalRareMeds with your prescription for current pricing and sourcing.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
